These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31112878)

  • 1. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis.
    Guo X; Sun H; Dong J; Feng Y; Li H; Zhuang R; Wang P; Cai W; Zhou Y
    Crit Rev Oncol Hematol; 2019 Jul; 139():16-23. PubMed ID: 31112878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
    Peng L; Bu Z; Ye X; Zhou Y; Zhao Q
    Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26537178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis.
    Taheri A; Rad A; Sadeghi E; Varshosaz J
    Curr Pharm Des; 2021; 27(17):2041-2055. PubMed ID: 32940171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of peripheral neuropathy induced by standard and nanoparticle albumin-bound paclitaxel in rats.
    Yamashita Y; Egashira N; Masuguchi K; Ushio S; Kawashiri T; Oishi R
    J Pharmacol Sci; 2011; 117(2):116-20. PubMed ID: 21897056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway.
    Sun H; Guo X; Wang Z; Wang P; Zhang Z; Dong J; Zhuang R; Zhou Y; Ma G; Cai W
    Oxid Med Cell Longev; 2019; 2019():3142732. PubMed ID: 30881589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
    Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
    Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
    Kanbayashi Y; Sakaguchi K; Ishikawa T; Ouchi Y; Nakatsukasa K; Tabuchi Y; Kanehisa F; Hiramatsu M; Takagi R; Yokota I; Katoh N; Taguchi T
    Breast; 2020 Feb; 49():219-224. PubMed ID: 31901783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Kida K; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Doi T; Oba M; Endo I; Ishikawa T
    Breast Cancer; 2024 May; 31(3):409-416. PubMed ID: 38453739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
    Ohno T; Mine T; Yoshioka H; Kosaka M; Matsuda S; De Kerckhove M; De Kerckhove C; Irie J; Inoue K; Haraguchi M; Kitajima M; Shinichiro I; Tokai H; Tanaka T; Izumida R
    Anticancer Res; 2014 Aug; 34(8):4213-6. PubMed ID: 25075049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
    Kudlowitz D; Muggia F
    Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.
    Tsuyuki S; Yamagami K; Yoshibayashi H; Sugie T; Mizuno Y; Tanaka S; Kato H; Okuno T; Ogura N; Yamashiro H; Takuwa H; Kikawa Y; Hashimoto T; Kato T; Takahara S; Katayama T; Yamauchi A; Inamoto T
    Breast; 2019 Oct; 47():22-27. PubMed ID: 31302389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
    Kanbayashi Y; Sakaguchi K; Ishikawa T; Tabuchi Y; Takagi R; Yokota I; Katoh N; Takayama K; Taguchi T
    Med Oncol; 2022 Jul; 39(10):153. PubMed ID: 35852641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
    Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
    Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
    Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
    Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
    Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
    Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
    Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
    Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
    Kundranda MN; Niu J
    Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
    Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.